MX2020001262A - Compuestos de platino a base de lipido y nanoparticulas. - Google Patents

Compuestos de platino a base de lipido y nanoparticulas.

Info

Publication number
MX2020001262A
MX2020001262A MX2020001262A MX2020001262A MX2020001262A MX 2020001262 A MX2020001262 A MX 2020001262A MX 2020001262 A MX2020001262 A MX 2020001262A MX 2020001262 A MX2020001262 A MX 2020001262A MX 2020001262 A MX2020001262 A MX 2020001262A
Authority
MX
Mexico
Prior art keywords
nanoparticles
based compounds
lipid
platinum based
platinum compounds
Prior art date
Application number
MX2020001262A
Other languages
English (en)
Inventor
Monideepa Roy
Arindam Sarkar
Sk Samad Hossain
Aniruddha Sengupta
Pradip Kumar Dutta
Aasif Ansari
Swadhin K Mandal
Shiladitya Sengupta
Aniruddha Sengpta
Original Assignee
Akamara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akamara Therapeutics Inc filed Critical Akamara Therapeutics Inc
Publication of MX2020001262A publication Critical patent/MX2020001262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción se relaciona al campo de nanotecnología y agentes terapéuticos de cáncer. En particular, la presente descripción se relaciona a compuestos a base de platino que comprenden porción de platino, porción enlazadora y porción de lípido y nanopartículas correspondientes de los mismos. La descripción además se relaciona a la síntesis de los compuestos a base de platino, nanopartículas y composiciones que comprenden los compuestos/nanopartículas a base de platino. La descripción también se relaciona a métodos para manejar cáncer al emplear los compuestos de carbeno antedichos, los compuestos a base de platino, nanopartículas y composiciones de los mismos.
MX2020001262A 2013-06-14 2015-12-11 Compuestos de platino a base de lipido y nanoparticulas. MX2020001262A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1781DE2013 2013-06-14

Publications (1)

Publication Number Publication Date
MX2020001262A true MX2020001262A (es) 2020-09-22

Family

ID=52022859

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017123A MX2015017123A (es) 2013-06-14 2014-06-13 Compuestos de platino a base de lipido y nanoparticulas.
MX2020001262A MX2020001262A (es) 2013-06-14 2015-12-11 Compuestos de platino a base de lipido y nanoparticulas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015017123A MX2015017123A (es) 2013-06-14 2014-06-13 Compuestos de platino a base de lipido y nanoparticulas.

Country Status (11)

Country Link
US (4) US10017531B2 (es)
EP (1) EP3007709B1 (es)
JP (2) JP6800748B2 (es)
CN (1) CN105705152B (es)
AU (2) AU2014278011B2 (es)
BR (1) BR112015031278B1 (es)
CA (1) CA2915357C (es)
MX (2) MX2015017123A (es)
RU (2) RU2737735C2 (es)
WO (2) WO2014201376A2 (es)
ZA (1) ZA201600099B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201376A2 (en) 2013-06-14 2014-12-18 Invictus Oncology Pvt. Ltd. Lipid-based platinum compounds and nanoparticles
KR102085190B1 (ko) * 2015-04-13 2020-03-05 더 유니버시티 오브 홍콩 Oled 어플리케이션용 금 착물
RU2017144237A (ru) * 2015-05-19 2019-06-20 Акамара Терапьютикс, Инк. Способ получения супрамолекулярных платиновых соединений
CN109678910B (zh) * 2016-01-25 2021-09-07 沈阳药科大学 一种化合物及其应用以及一种铂类配合物及其脂质体
MX2018009727A (es) 2016-02-11 2018-12-17 Invictus Oncology Pvt Ltd Inhibidores de señalizacion celular, sus formulaciones y metodos de uso.
EP3458462A1 (en) 2016-05-18 2019-03-27 Akamara Therapeutics, Inc. Crystalline platinum-based compounds
CN106317124B (zh) * 2016-07-27 2018-08-21 东南大学 一种自旋交叉中空纳米球及其制备方法和应用
KR20190045295A (ko) * 2016-09-07 2019-05-02 아카마라 테라퓨틱스, 인크. 백금 기재 화합물에 의한 면역 기억 유도
CN108689939A (zh) * 2017-04-07 2018-10-23 厦门华绰生物医药科技有限公司 取代咪唑盐类化合物、其制备方法、药用组合物及其应用
CN107417752B (zh) * 2017-07-26 2020-05-05 中国科学院长春应用化学研究所 一类具有抗癌活性的化合物及其制备方法和应用
WO2019097462A1 (en) * 2017-11-17 2019-05-23 Suresh Sarasija Cisplatin nanoparticle composition, method for the preparation thereof
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates
CN108579809B (zh) * 2018-01-23 2020-10-16 湖州师范学院 一种含氮杂环卡宾钯化合物的纳米颗粒催化剂及其制备方法
WO2020014387A1 (en) 2018-07-10 2020-01-16 Akamara Therapeutics, Inc. B-cell immunotherapy in cancer treatment
WO2020168283A1 (en) 2019-02-14 2020-08-20 Akamara Therapeutics, Inc. Compounds and methods for managing cancer through immune system
WO2020190907A1 (en) * 2019-03-18 2020-09-24 Kent State University Amphiphilic platinum (iv) prodrug and cancer treatment process
EP4237091A1 (en) * 2020-10-30 2023-09-06 The Regents Of The University Of California A silicasome nanocarrier for metal-based drug delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3783049A (en) 1971-03-31 1974-01-01 Trw Inc Method of platinum diffusion
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
JPH11508231A (ja) 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質／核酸複合体を含む送達ビヒクル
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6218367B1 (en) 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
US7611733B2 (en) 2004-03-26 2009-11-03 Cell Therapeutics Europe S.R.L. Nanoparticle formulations of platinum compounds
CA2576834A1 (en) * 2004-09-01 2006-03-09 Platco Technologies (Proprietary) Limited Preparation of platinum(ii) complexes
US7208611B2 (en) * 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
KR101430774B1 (ko) * 2006-06-26 2014-08-18 바스프 에스이 가교된 카르벤 리간드를 갖는 ｐｔ- 및 ｐｄ-비스- 및 테트라-카르벤 착물의 ｏｌｅｄ에서의 용도
JP5844642B2 (ja) * 2009-02-04 2016-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ナノスケール白金化合物およびその使用方法
AU2011284866A1 (en) 2010-07-28 2013-02-21 Basf Se Phosphinic acid hydrazide flame retardant compositions
WO2012177935A1 (en) * 2011-06-21 2012-12-27 Massachusetts Inistitute Of Technology Compositions and methods for the treatment of cancer
CN103917587A (zh) 2011-11-15 2014-07-09 巴斯夫欧洲公司 作为阻燃剂的p-哌嗪化合物
US9884123B2 (en) * 2012-01-03 2018-02-06 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
MX2014015764A (es) 2012-06-28 2015-04-10 Daihachi Chem Ind Agente retardante de llama, composicion de resina acuosa retardadora de llama y composicion de resina de uretano retardadora de llama que contiene dicho agente retardador de llama y por lo tanto su uso.
WO2014201376A2 (en) 2013-06-14 2014-12-18 Invictus Oncology Pvt. Ltd. Lipid-based platinum compounds and nanoparticles

Also Published As

Publication number Publication date
RU2016100741A (ru) 2017-07-24
WO2014201376A2 (en) 2014-12-18
JP2016522220A (ja) 2016-07-28
WO2014199352A2 (en) 2014-12-18
US10081648B2 (en) 2018-09-25
RU2679896C2 (ru) 2019-02-14
ZA201600099B (en) 2019-03-27
CA2915357C (en) 2023-10-03
EP3007709B1 (en) 2021-12-08
WO2014201376A3 (en) 2015-02-05
US20160122377A1 (en) 2016-05-05
WO2014199352A3 (en) 2015-04-16
BR112015031278A8 (pt) 2019-10-01
US20200354394A1 (en) 2020-11-12
AU2020204076A1 (en) 2020-07-09
US20160145284A1 (en) 2016-05-26
EP3007709A2 (en) 2016-04-20
AU2014278011A1 (en) 2016-01-07
US10017531B2 (en) 2018-07-10
JP2020125296A (ja) 2020-08-20
RU2016100741A3 (es) 2018-03-05
US10730899B2 (en) 2020-08-04
RU2737735C2 (ru) 2020-12-02
RU2019101651A3 (es) 2019-07-17
BR112015031278B1 (pt) 2022-05-17
JP6800748B2 (ja) 2020-12-16
US20190002489A1 (en) 2019-01-03
RU2019101651A (ru) 2019-05-14
CN105705152A (zh) 2016-06-22
MX2015017123A (es) 2016-08-03
CA2915357A1 (en) 2014-12-18
AU2014278011B2 (en) 2020-03-19
EP3007709A4 (en) 2017-03-15
CN105705152B (zh) 2021-07-09

Similar Documents

Publication Publication Date Title
MX2020001262A (es) Compuestos de platino a base de lipido y nanoparticulas.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
SG10201900948PA (en) Modified nucleotide linkers
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
EP3077399A4 (en) Methods useful in the synthesis of halichondrin b analogs
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
TWD164114S (zh) 行動電源之部分
ECSP14013327A (es) Compuestos con actividad nematicida
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
TWD159981S (zh) 化粧品容器
IN2015DN03898A (es)
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
BR112013023438A2 (pt) sistemas e métodos para melhorar o rendimento do etanol
IN2015DN03897A (es)
SG11201601790QA (en) Estimation of mixing factors to generate high-band excitation signal
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX2015007727A (es) 6-cloro-3-(fenil-d5)inden-1-ona y su uso.
IN2015DN00085A (es)
CR20140531A (es) Derivados de ariletinilo
MX2015014470A (es) Analogos de combretastatina.
CR20150028A (es) Derivados de ariletinilo
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.